Group 1 - Molina Healthcare Inc. (NYSE:MOH) is considered one of the most undervalued mid-cap stocks currently available for investment [1] - Goldman Sachs lowered its price target for Molina Healthcare to $124 from $167 while maintaining a Neutral rating after the company's Q4 2025 earnings miss [1][4] - UBS analyst AJ Rice also reduced the price target for Molina Healthcare to $145 from $170, citing challenges in the Medicaid and exchanges backdrop while keeping a Neutral rating [3] Group 2 - The return profiles for strong operators in low-margin, government-priced cyclical businesses, such as managed care organizations, can diminish rapidly during economic downturns [2] - Goldman Sachs anticipates that challenges in the managed care sector will persist due to its sensitivity to the current cyclical environment [2]

Company Overview - Molina Healthcare (MOH) is a managed healthcare provider serving over 5.6 million members across Medicaid, Medicare, and Marketplace programs in 21 states, with Medicaid accounting for approximately 75% of premium revenue [15][16]. - The company is currently facing a challenging margin environment, marking the second consecutive year of industry-wide losses due to post-COVID redeterminations that removed around 17 million beneficiaries from Medicaid rolls [16]. Financial Performance - Despite industry headwinds, Molina continues to generate profit, with a medical loss ratio (MLR) approximately 250 basis points better than the industry average [18]. - Management expects Medicaid to generate roughly $16 per share of earnings in 2025, with a conservative estimate of approximately $14 of EPS from Medicaid for 2026 [18]. - Each 100 basis point improvement in Medicaid MLR translates to about $4.50 in incremental EPS for the company [19]. Growth Potential - Molina's management targets 11-13% annual premium growth, largely from strategic contract wins, with embedded earnings from recently awarded contracts amounting to roughly $8.65 per share [21]. - If Medicaid rates revert toward the high end of management's long-term MLR guidance, Molina could earn approximately $37 per share in 2028, assuming a 4.5% pretax margin [23]. - The company has repurchased $1 billion of stock year-to-date, including 5.3% of shares in the most recent quarter, and has plans for additional buybacks [24]. Valuation and Market Position - Molina's five-year average multiple is approximately 15x earnings, suggesting significant upside potential; applying a 13x multiple to $40 of 2028 EPS yields a share price of roughly $520, representing approximately 225% upside from current levels [25]. - Concerns regarding the long-term role of managed care organizations in Medicaid are viewed as overstated, as approximately 75% of Medicaid beneficiaries currently receive care through HMOs [22].

Company Overview - Molina Healthcare, Inc. is a leading provider of managed healthcare services focused on government-sponsored programs such as Medicaid and Medicare [6] - The company serves low-income families, individuals, and seniors eligible for Medicaid and Medicare in 18 U.S. states, with approximately 5.2 million members as of December 31, 2021 [7] - Revenue for the trailing twelve months (TTM) is $54.07 billion, with a net income of $883 million and a market capitalization of $7.50 billion [5] Recent Developments - Cobalt Capital Management disclosed a new position in Molina Healthcare, acquiring 115,000 shares valued at approximately $22.01 million, which represents 10.11% of the fund's reportable assets [2][3] - As of November 13, 2025, Molina Healthcare's stock price was $138.48, reflecting a decline of 55.23% over the past year, underperforming the S&P 500 by 69.17 percentage points [4] Investment Insights - Cobalt Capital's significant investment suggests a belief that the market has misjudged the company's potential, indicating a gap between the stock's decline and Molina's cash-generating capabilities [10] - The company's revenue model relies on government contracts that pay a fixed amount per member, making financial performance dependent on effective management of medical costs [11] - Recent challenges in rate negotiations and rising medical costs have negatively impacted the stock price, but the underlying business retains advantages that could support future growth [12]

Core Viewpoint - Molina Healthcare is facing significant operational and financial challenges, with declining Medicaid enrollment and increasing costs impacting profitability and outlook [2][3][6]. Company Overview - Molina Healthcare provides managed healthcare services primarily to low-income families and individuals through Medicare and Medicaid programs [1]. Financial Performance - The company has missed earnings estimates in three of the last four quarters, with a notable miss of -53.65% in Q3, resulting in a trailing four-quarter average earnings miss of -15.8% [6]. - Analysts have revised fourth-quarter earnings estimates down by -87.28% over the past 60 days, with the current Zacks Consensus EPS Estimate at 43 cents, reflecting a negative growth of -91.5% year-over-year [7][8]. Operational Challenges - Medicaid membership has declined by 5.2% in the first nine months of 2025, indicating difficulties in enrollment growth [2]. - Operating expenses have consistently increased, leading to pressure on margins and a worsening medical care ratio [3]. Industry Context - Molina Healthcare is ranked as a Zacks Rank 5 (Strong Sell) and is part of the bottom 16% of the Zacks Medical – HMOs industry group, which is expected to underperform the market in the next 3 to 6 months [4]. - The stock has been underperforming, hitting a 52-week low last month, and is considered a compelling short opportunity [5]. Technical Analysis - The stock is in a sustained downtrend, trading below both the 50-day and 200-day moving averages, indicating bearish sentiment [9][12]. - A "death cross" has occurred, suggesting that significant upward movement would be required to consider long positions [12]. Final Assessment - The combination of deteriorating fundamentals, negative earnings revisions, and inclusion in a poorly performing industry group suggests that Molina Healthcare is unlikely to see significant recovery in the near term [13][14].

Core Insights - Molina Healthcare stock (NYSE: MOH) has experienced a decline of approximately 27% over the past month due to significant negative developments following its Q3 2025 report, yet it remains a potential investment opportunity due to historical rebound patterns [2][5] Financial Performance - Q3 profitability has substantially decreased, leading to a cut in the full-year earnings forecast [5] - Revenue growth has been reported at 13.7% for the last twelve months (LTM) and an average of 12.8% over the last three years [6] - The minimum annual revenue growth in the last three years was 6.7% [6] - The stock trades at a price-to-earnings (PE) multiple of 8.4 [6] Operational Challenges - Rising medical costs within the Marketplace business segment are a concern [5] - The company faces external pressures from market anxiety regarding new regulatory proposals and several shareholder lawsuits [5] Market Position - The stock is currently trading within a historically significant support range of $133.85 to $147.95, where it has attracted strong buying interest on three separate occasions over the last decade [5] - Following previous rebounds from this support range, MOH stock has generated an average peak return of 75.7% [5] Cash Flow Metrics - The company has reported a nearly -1.3% free cash flow margin and a 3.0% operating margin for the last twelve months [6]

Core Viewpoint - Molina Healthcare, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims related to undisclosed adverse financial information during the specified class period from February 5, 2025, to July 23, 2025 [1][3]. Summary by Sections Class Action Details - The lawsuit is titled Hindlemann v. Molina Healthcare, Inc., and investors who acquired Molina securities during the class period have until December 2, 2025, to seek lead plaintiff status [1][2]. - The law firm Robbins Geller Rudman & Dowd LLP is representing the plaintiffs in this case [7]. Allegations Against Molina Healthcare - The lawsuit alleges that Molina Healthcare failed to disclose critical information regarding its medical cost trend assumptions and the dislocation between premium rates and medical costs [3]. - It is claimed that Molina's near-term growth relied on reduced utilization of various healthcare services, which was not communicated to investors [3]. Financial Performance and Impact - On July 7, 2025, Molina reported adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines [4]. - Following this announcement, Molina's stock price declined significantly, reflecting investor concerns over the company's financial guidance being cut by 10.2% at the midpoint for fiscal year 2025 [4]. - On July 23, 2025, Molina further reduced its full-year earnings guidance, reporting a GAAP net income of $4.75 per diluted share for Q2 2025, an 8% decrease year-over-year, and attributing this to a challenging medical cost trend environment [5]. The stock price fell nearly 17% after this news [5].

Company Overview - Molina Healthcare has a market capitalization of $7.8 billion and provides managed healthcare services primarily to low-income families and individuals through Medicaid, Medicare, and state insurance marketplaces [2]. Recent Developments - In Q3 2025, Molina Healthcare reported adjusted earnings of $1.84 per share on premium revenue of $10.8 billion, which fell short of Wall Street expectations [4]. - The company recently reduced its full-year earnings guidance to $14 per share, down from an earlier forecast of $19 per share, and significantly lower than the initial projection of $24.50 per share at the start of 2025 [5]. Financial Performance - The disappointing Q3 results were attributed to rising medical costs and increased healthcare utilization, with the consolidated medical care ratio reaching 92.6% for the quarter [5]. - The Marketplace business, which constitutes 10% of total revenue, faced significant challenges, with its medical care ratio soaring to 95.6%. Management now anticipates a $2-per-share loss for the Marketplace segment, a drastic change from the previous expectation of over $3 per share in profits [6]. Medicaid Business - Despite challenges, the core Medicaid business, which accounts for 75% of premium revenue, continues to perform relatively well, with medical cost trends in Medicaid reaching 7% for the year, surpassing the negotiated rate increase of 5.5% with states [7]. Investment Activity - Notably, investor Michael Burry has taken a position in Molina Healthcare, acquiring 125,000 shares, which are currently down over 60% from their all-time highs [1].

Core Viewpoint - A lawsuit has been filed against Molina Healthcare, Inc. and certain senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Group 1: Lawsuit Details - Investors have until December 2, 2025, to request to lead the case, which is pending in the U.S. District Court for the Central District of California [2]. - The lawsuit is titled Hindlemann v. Molina Healthcare, Inc., et al., No. 25-cv-9461 [2]. Group 2: Company Background - Molina Healthcare is a health insurance company providing managed healthcare services to low-income individuals under Medicaid and Medicare programs [3]. - The company previously claimed a "solid" earnings growth profile heading into 2025 and stated it was monitoring utilization patterns to mitigate healthcare cost inflation [3]. Group 3: Financial Performance and Stock Impact - On July 7, 2025, Molina reported Q2 2025 adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines [4]. - The company cut its guidance for expected adjusted earnings per share by 10.2% to a range of $21.50 to $22.50 per share [4]. - Following further revelations on July 23, 2025, regarding full-year adjusted earnings expectations of no less than $19.00 per diluted share, Molina's stock price fell by $32.03, or 16.8%, from $190.25 to $158.22 per share [4].

Core Viewpoint - A lawsuit has been filed against Molina Healthcare, Inc. and certain senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Group 1: Lawsuit Details - Investors have until December 2, 2025, to request to lead the case, which is pending in the U.S. District Court for the Central District of California [2]. - The lawsuit is titled Hindlemann v. Molina Healthcare, Inc., et al., No. 25-cv-9461 [2]. Group 2: Company Background - Molina Healthcare is a health insurance company providing managed healthcare services to low-income individuals under Medicaid and Medicare programs [3]. - The company previously claimed a "solid" earnings growth profile heading into 2025 and stated it was monitoring utilization patterns to mitigate healthcare cost inflation [3]. Group 3: Financial Performance and Stock Impact - On July 7, 2025, Molina reported Q2 2025 adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines [4]. - The company cut its guidance for expected adjusted earnings per share by 10.2% to a range of $21.50 to $22.50 per share [4]. - Following further revelations on July 23, 2025, Molina adjusted its full-year 2025 earnings expectation to no less than $19.00 per diluted share, citing a challenging medical cost trend environment [4]. - The stock price fell by $32.03 per share, or 16.8%, from $190.25 on July 23, 2025, to $158.22 on July 24, 2025, in response to these announcements [4].

Core Viewpoint - Molina Healthcare, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims related to undisclosed adverse financial conditions and misleading earnings guidance during the specified class period [1][4][5]. Company Summary - Molina Healthcare provides managed healthcare services primarily to low-income families and individuals through Medicaid, Medicare, and state insurance marketplaces [3]. - The company has been accused of failing to disclose critical information regarding its medical cost trend assumptions and the dislocation between premium rates and medical costs [4]. Financial Performance - On July 7, 2025, Molina Healthcare reported adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines [5]. - Following this announcement, the company's stock price experienced a decline, reflecting investor concerns over its financial outlook [5]. - On July 23, 2025, Molina Healthcare further cut its full-year 2025 earnings guidance, reporting a GAAP net income of $4.75 per diluted share for Q2 2025, an 8% decrease year-over-year, and projecting adjusted earnings of no less than $19.00 per diluted share for the full year [6]. - The stock price fell nearly 17% after this announcement, indicating significant market reaction to the revised earnings outlook [6]. Legal Proceedings - The class action lawsuit allows investors who purchased Molina Healthcare securities during the class period to seek appointment as lead plaintiff, representing the interests of all class members [7]. - Robbins Geller Rudman & Dowd LLP is the law firm leading the class action, which has a strong track record in securities fraud litigation [8].